Aptose Biosciences Inc

Aptose Biosciences — Investor Presentation (June 2022)

44 slides from Aptose Biosciences's investor presentation, Jun 27, 2022

  1. Slide 1: Aptose Corporate Presentation

    PRECISION ONCOLOGY FOR THERAPIES OF TOMORROW PRECISION ONCOLOGY FOR THERAPIES OF TOMORROW Aptose Corporate Presentation NASDAQ: APTO TSX: APS June 27, 2022

  2. Slide 2: Disclosure

    Disclosure This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or i nvi tation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or assets of

  3. Slide 3: Aptose Biosciences: Clinical Stage Oncology Company

    Aptose Biosciences (NASDAQ: APTO) Clinical Stage Oncology Company ᄫ Focused on Precision Medicines Developing highly differentiated oral kinase inhibitors for hematologic malignancies Experienced leadership with deep expertise in kinase inhibitors & orphan diseases Planned value - driving clinical u

  4. Slide 4: Aptose Leadership Team: Multifaceted Expertise in Therapeutic Development

    Aptose Leadership Team : Multifaceted Expertise in Therapeutic Development 4 William G. Rice, PhD Chairman, President & Chief Executive Officer Philippe Ledru Sr. VP & Chief Commercial Officer Rafael Bejar , MD, PhD Sr. VP & Chief Medical Officer Fletcher Payne Sr. VP & Chief Financial Officer

  5. Slide 5: Aptose SAB: Distinguished Opinion Leaders with Deep Oncology Expertise

    Aptose SAB : Distinguished Opinion Leaders with Deep Oncology Expertise 5 Brian J. Druker, MD Pioneer in the field of precision medicine Key Role in development of Gleevec - the first targeted kinase inhibitor for cancer Member, National Academy of Medicine, National Academy of Sciences & American A

  6. Slide 6: Aptose Clinical Stage Pipeline: Oral Kinase Inhibitors

    Aptose Clinical Stage Pipeline: Oral Kinase Inhibitors that Cover a Broad Spectrum of Hematologic Malignancies 6 Program Target Indication Preclinical Phase 1 Proof - of - Concept Phase 2/3 Registrational HM43239 Myeloid Kinome AML Luxeptinib Myeloid Kinome AML, MDS Luxeptinib Lymphoid Kinome B - ce

  7. Slide 7: HM43239 Oral Myeloid Kinome Inhibitor

    7 HM43239 “239” Oral Myeloid Kinome Inhibitor

  8. Slide 8: HM43239 Proven Clinical Activity in AML Patients with Significant Unmet Needs

    HM43239 Proven Clinical Activity in AML Patients with Significant Unmet Needs 8 HM43239 Myeloid Kinome Inhibitor Single Agent Activity 3 doses with CRc and no drug - related SAE Well tolerated No drug - related SAE, QTc toxicities, or CK increases Validated AML Targets FLT3, SYK, JAK1/2, cKIT MUT Ac

  9. Slide 9: AML in the US: Continued Unmet Need for More Effective and Safe Therapies

    AML in the US : Estimated 20,240 new cases and 11,400 deaths in 2021 Continued Unmet Need for More Effective and Safe Therapies 9 Epidemiology US (2021) EU5 (2020) Japan (2021) China (2020) Leukemia Incidence 3 61,090 1 51,820 3 14,600 7 85,400 AML Incidence 20,240 2 16,580 3 a 6,570 7c 31,430 3b 5

  10. Slide 10: HM43239 Kinase Inhibitory Profile

    HM43239 Kinase Inhibitory Profile: Predicts Clinical Activity in AML Patients Harboring Mutated FLT3, Unmutated FLT3, and Having a Diverse Collection of Adverse Mutations 10 Potent suppression of driver and compensatory kinases operative in AML • All forms of FLT3 : - ITD, - TKD, - GK mutations and

  11. Slide 11: HM43239 Suppresses P-FLT3 / P-SYK and Downstream Pathways in AML Cell Lines

    HM43239 Suppresses P - FLT3 / P - SYK and the P - STAT / P - ERK Downstream Pathways in AML Cell Lines MV - 4 - 11 MOLM - 14 MV - 4 - 11 MOLM - 14 Confirmation of P - SYK Inhibition by HM43239 with Flow Cytometry in MV - 4 - 11 and MOLM - 14 AML Cells MV - 4 - 11 MOLM - 14 BAF3/ITD HM43239 (nM) HM43

  12. Slide 12: HM43239 In Vivo Models Suggest Superior Antitumor Activity

    HM43239 In Vivo Models Suggest Superior Antitumor Activity and Favorable Tolerability Relative to Established Kinase Inhibitors in AML MOLM - 14 ITD/F691L - MUT AML cells used with an in vivo murine xenograft model: • MOLM - 14 ITD/F691L - MUT is an AML cell harboring the ITD and F691L dual mutant f

  13. Slide 13: HM43239 Superior to Gilteritinib in AML Models Conducted in Mice

    HM43239 Superior to Gilteritinib in AML Models Conducted in Mice: AML with FLT3 - ITD/F691L Mutations Resistant to Gilteritinib FLT3 Inhibitor 13 HM43239 more potent than gilteritinib : Subcutaneous AML model resistant to gilteritinib Three million MOLM - 14 FLT3 - ITD/ F691L cells were implanted SC

  14. Slide 14: HM43239 In Vivo Models Suggest Synergy with DNMT, BCL-2, MDM-2 Inhibitors

    HM43239 In Vivo Models Suggest Synergy with Inhibitors of DNMT, BCL - 2, or MDM - 2, and Combinatorial Optionality in AML HM43239, in subcutaneous xenograft, superior efficacy to Gilt or Aza alone and combines effectively with each against MOLM - 14 ITD/F691L - MUT AML HM43239, in subcutaneous xenog

  15. Slide 15: HM43239 Preclinical Data Position for Broad Clinical Success in AML

    HM43239 Preclinical Data Position for Broad Clinical Success in AML Patients • Positioned as Superior to Other FLT3 Inhibitors • Inhibits all forms of FLT3 • Kills AML cells and treats AML disease in animals resistant to other approved FLT3 inhibitors • Positioned as a FLT3/SYK/JAK Inhibitor for AML

  16. Slide 16: HM43239 Phase 1/2 Study in R/R AML: Dose Escalation & Exploration

    HM43239 Phase 1/2 Study in R/R AML: Ongoing Dose Escalation & Dose Exploration 16 PART A : DOSE ESCALATION PART B : DOSE EXPLORATION Cohort 6 200 mg QD Ongoing Cohort 5 160 mg QD Completed Cohort 4 120 mg QD Completed Cohort 3 80 mg QD Completed Cohort 2 40 mg QD Completed Cohort 1 20 mg QD Complete

  17. Slide 17: HM43239 Swimmers' Plots of R/R AML Patients

    HM32239 Swimmers’ Plots of R/R AML Patients Dosed Through Cut - off Date of 31May2022 17 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 Weeks on Study Treatment Safety Follow-up 200 mg 160 mg 120 mg 80 mg 40 mg 20 mg 20 20 40 80 80 80 80 120 120 120 160 160 160 160 200 200 200 200 1 2 3 4 5 6 7* 8 9

  18. Slide 18: HM43239 Demonstrates Dose-Dependent PK and Target Engagement

    HM43239 Demonstrates Dose - Dependent PK and Target Engagement 18 Plasma inhibitory activity (PIA) Assay Measures the ability of patient plasma to inhibit phospho - FLT3 in MOLM - 14 reporter cell line FINDINGS: PIA was dose - dependent with up to 90% phospho - FLT3 inhibition at dose levels ≥ 80 mg

  19. Slide 19: HM43239 Phase 1/2 Study: Pharmacokinetic Properties

    LLOQ = 0.001 µM 0.0001 0.001 0.01 0.1 1 10 M e a n H M 4 3 2 3 9 C o n c e n t r a t i o n ( µ M ) 0.0519 0.5191 5.191 51.91 519.1 5191 M e a n H M 4 3 2 3 9 C o n c e n t r a t i o n ( n g / m L ) 0 1 2 3 4 6 8 10 24 32 48 Nominal Time (hours) 200 mg (n=4)160 mg (n=8)120 mg (n=12)80 mg (n=19)40 mg

  20. Slide 20: HM43239 Patients Who Achieved a Clinical Response to Date

    HM43239 Patients Who Achieved a Clinical Response to Date in Phase 1/2 Study of R/R AML Patients 20 Abbreviation: CR, complete response; CRi, complete response with incomplete hematologic recovery; CRp , complete response with incomplete platelet recovery; HSCT, hematopoietic stem cell transplantati

  21. Slide 21: HM43239 AML Patients with Best Clinical Responses to Date

    HM43239 AML Patients with Best Clinical Responses to Date Observed 7 CRc and 1 PR in Diverse and Challenging Patient Populations 21 R/R AML FLT3 Mutated FLT3 Un - mutated FLT3 - ITD FLT3 - ITD FLT3 - ITD Prior Mido /Gilt FLT3 - WT FLT3 - WT Normal Cytogenetics Abnormal Cytogenetics Abnormal Cytogene

  22. Slide 22: HM43239 Safety and Efficacy Data Revealed a Broad Therapeutic Window

    HM43239 Safety and Efficacy Data Revealed a Broad Therapeutic Window • Safety Profile Favorable to Date ― No drug related SAE ― No drug related deaths ― No drug related AE of elevated CK ― No drug related AE of QT prolongation – No observed relation between D QTc and dose ― No DLT up to 160 mg and o

  23. Slide 23: HM43239 Teachings Guide the Planned Expansion Clinical Studies

    HM43239 Teachings from Phase 1 Guide the Planned Expansion Clinical Studies • Current Dose Escalation/Dose Exploration Phase 1 Trial in R/R AML Patients — Demonstrated CRc in FLT3 - Mutant AML and received Fast Track Designation in FLT3 - Mutant R/R AML — Selected 3 Expansion Doses (80 mg, 120 mg, 1

  24. Slide 24: Next Step Planned as Phase 1 Expansion Trials (2H2022)

    HM43239 + Venetoclax HM43239 single agent (≥ 50% with prior FLT3i ) HM43239 Next Step Planned as Phase 1 Expansion Trials (2H2022) to Provide Data Intended to Support Registrational Studies Group Assignment * R/R AML Patient Stratification ARM 1 FLT3 - Mutated ( - ITD, - TKD, - GK) +/ - prior FLT3i

  25. Slide 25: Major Objectives and AML Target Populations Sought for HM43239

    Major Objectives and AML Target Populations Sought for HM43239 25 1 R/R AML FLT3+ post FLT3 inhibitor : Limited treatment options for patients 2 R/R AML FLT3+ through combination: Build upon standard of care for patients in combination with with BCL2i and/or HMAs 3 R/R AML FLT3 - Unmutated with adve

  26. Slide 26: HM43239 Overall Response Rate in Phase 1 as a Single Agent in R/R AML

    HM43239 Overall Response Rate (7 CRc and 1 PR) to Date in Phase 1 as a Single Agent in R/R AML Patients 26 Abbreviation: CR, complete remission; CRc, composite complete remission; CRp, complete remission with incomplete platelet rec ove ry; CRi, complete remission with incomplete hematological recov

  27. Slide 27: HM43239 Clinically Validated, Once Daily, Oral Myeloid Kinome Inhibitor

    27 Targets Constellation of Kinases Important in Myeloid Cancers • Potent inhibitor of kinases associated with malignant transformation and resistance • Highly active in vivo against FLT3 internal tandem duplication ( ITD ), resistance - conferring tyrosine kinase domain mutations ( TKD ) , and gate

  28. Slide 28: Luxeptinib Oral Lymphoid & Myeloid Kinome Inhibitor

    28 Luxeptinib Oral Lymphoid & Myeloid Kinome Inhibitor

  29. Slide 29: Luxeptinib: Atypical, Dual Lymphoid and Myeloid Kinome Inhibitor

    Luxeptinib: Atypical, Dual Lymphoid and Myeloid Kinome Inhibitor 29 Inhibits WT and all mutant forms of BTK Inhibits WT and all mutant forms of FLT3 May avoid rapid emergence of drug resistance Mutation Agnostic Robust Safety Profile Simultaneously suppresses multiple oncogenic signaling pathways Av

  30. Slide 30: Three Peer Reviewed Research Articles on Luxeptinib

    30 Published three peer reviewed research articles illustrating the potential of Luxeptinib for application to multiple indications: AML Lymphomas Inflammation Autoimmunity

  31. Slide 31: Luxeptinib: Ongoing Phase 1a/b Study in Heavily Pretreated B-cell Malignancies

    Luxeptinib: Ongoing Phase 1a/b Study in Heavily Pretreated B - cell Malignancies 31 Cohort 6 900 mg Q12H Completed Cohort 5 750 mg Q12H Completed Cohort 4 600 mg Q12H Completed Cohort 3 450 mg Q12H Completed Cohort 2 300 mg Q12H Completed Cohort 1 150 mg Q12H Completed Dose Escalation Phase • Patien

  32. Slide 32: Luxeptinib: Swimmers' Plot of Patients with R/R B-Cell Malignancies

    Luxeptinib: Swimmers’ Plot of Heavily Pretreated Patients with R/R B - Cell Malignancies Treated with Luxeptinib 32 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 Weeks on Study Treatment Safety Follow-up On Study Treatment 900 mg (Cohort 6) 750 mg (Cohort 5) 600 mg (Cohort 4) 450 mg (Cohort 3) 300 m

  33. Slide 33: Luxeptinib: Waterfall Plot of Best Response

    FL DLBCL CLL RT CLL CLL SLL MCL SLL FL MCL WM * DLBCL SLL CLL DLBCL * FL * CLL FL CLL 5 3 3 5 713 2 2 43 4 67 12 4 2 2 2 3 25 3 3 5 713 2 2 43 4 67 12 4 2 2 2 3 2 IBR IBR IBR IBR IBRIBR IBR IBR IBR IBRIBR IBR IBR IBR IBRIBR IBR IBR IBR IBR 26 27 8 12 13 16 24 20 29 6 5 28 21**22 9 15 25 10 31 23 Pat

  34. Slide 34: Luxeptinib Case Study: Tumor Reduction and Complete Metabolic Response

    Luxeptinib Case Study: Significant Tumor Reduction (47% ) with Accompanying Complete Metabolic Response (CMR) in Patient with Refractory Follicular Lymphoma Follicular Lymphoma Complete Metabolic Response and Tumor Reduction Patient 72 - year - old Male with Follicular Lymphoma : Received 450mg BID

  35. Slide 35: Luxeptinib Case Study: Dose-dependent Anti-tumor Activity in Follicular Lymphoma

    Luxeptinib Case Study: Dose - dependent Anti - tumor Activity in a Patient with Refractory Follicular Lymphoma Follicular Lymphoma Significant Tumor Reduction and Well Tolerated Demographics 60 - year - old female Diagnosis at Study Entry Grade 1 FL Prior Therapies Failed • bendamustine + obinutuzum

  36. Slide 36: Luxeptinib: Ongoing Phase 1a/b Study in R/R AML and HR MDS

    Luxeptinib : Ongoing Phase 1a/b Study in R/R AML and HR MDS 36 Cohort 4 900 mg Q12H Ongoing Cohort 3 750 mg Q12H Completed Cohort 2 600 mg Q12H Completed Cohort 1 450 mg Q12H Completed Dose Escalation Phase • Oral capsules administered twice daily on a 28 - day cycle • Planned expansion cohorts afte

  37. Slide 37: Luxeptinib: Swimmers' Plot of Patients with R/R AML

    Luxeptinib: Swimmers’ Plot of Heavily Pretreated Patients with R/R AML Treated with Luxeptinib 37 1 29 57 85 113 141 169 197 225 253 281 309 337 365 393 421 Days on Study Treatment Safety Follow-up On Study Treatment 900 mg 750 mg 600 mg 450 mg 450 450 450 450 450 450 600 600 600 600 750 750 750 750

  38. Slide 38: Luxeptinib Case Study: Durable MRD-negative CR in FLT3+ Patient

    Luxeptinib Case Study : Durable MRD - negative CR in FLT3+ Patient with high plasma exposure levels FLT3 - ITD+ R/R AML CR / MRD - Demographics 46 - year - old male Diagnosis at Study Entry FLT3 - ITD+, relapsed de novo AML with myeloid sarcoma (bone marrow & extra medullary disease) Prior Therapies

  39. Slide 39: Luxeptinib Ongoing Activities

    Luxeptinib Ongoing Activities • Ongoing Clinical Development in Two Separate Trials and Patient Populations • Phase 1 trial in patients with R/R B - cell leukemias|lymphomas • Phase 1 trial in patients with R/R AML • Critical Step for Lux Program is the Transition to a Novel and Improved Formulation

  40. Slide 40: Luxeptinib: Single Dose G3 Formulation

    Luxeptinib: Single Dose G3 Formulation with 50 mg, 100mg, or 200 mg Dosages 40 • Patients participating in G3 study are derived from: • Ph 1 R/R B - cell cancers • Ph 1 R/R AML • 72 hr following single dose of G3: • Some received 750mg G1 • Some received 900mg G1 G3 Dose G1 Dose No. Patients 50 mg 7

  41. Slide 41: Luxeptinib: First Patient Dosed with G3 Formulation

    0.001 0.01 0.1 1 10 0 4 8 12 16 20 24 Hours Post Dosing Plasma Concentration ( uM ) PK Comparison of 50mg G3 to 900mg G1 Luxeptinib in AML Patient G3 50mg G1 900mg G1 150mg 0.001 0.01 0.1 1 10 0 24 48 72 96 PK Comparison of 50mg G3 to 900mg G1 Luxeptinib in AML Patient Hours Post Dosing Plasma Conce

  42. Slide 42: Luxeptinib: Findings to Date and Next Steps in 2022

    42 Targets Kinases Important in Lymphoid and Myeloid Cancers • Inhibits BTK , FLT3 , CSF1R, PDGFR α , TRK, AURK, others • Generally w ell - tolerated – currently dosing at 900mg BID with original formulation • Delivered antitumor activity in diverse B - cell cancers • Delivered MRD - CR in relapsed

  43. Slide 43: Aptose Biosciences: Clinical Stage Oncology Company

    Aptose Biosciences (NASDAQ: APTO) Clinical Stage Oncology Company ᄫ Focused on Precision Medicines D eveloping highly differentiated oral kinase inhibitors for hematologic malignancies Experienced leadership with deep expertise in kinase inhibitors & orphan diseases Planned value - driving clinical

  44. Slide 44: Precision Oncology for Therapies of Tomorrow

    PRECISION ONCOLOGY FOR THERAPIES OF TOMORROW PRECISION ONCOLOGY FOR THERAPIES OF TOMORROW We thank our partners, investigators, and investors for helping us bring novel drugs to patients with the greatest need.

Aptose Biosciences — Investor Presentation (June 2022) on 6ix